Ulixertinib for people with histiocytic neoplasms
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests an oral targeted therapy called ulixertinib for people with histiocytic neoplasms (a rare group of blood cell disorders). It aims to see if the drug can shrink tumors or control the disease in patients who have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of a histiocytic neoplasm (a type of blood cell disorder).
- Your tumor must have a change (mutation) in a specific gene in the MAPK pathway, like BRAF, NRAS, or KRAS.
- Your disease must be measurable on a scan (like a CT or MRI).
- You must be at least 12 years old (if under 18, other age-specific rules apply).
- Your cancer must have come back, not responded, or you cannot tolerate other treatments like chemotherapy or targeted drugs.
- You must have adequate kidney, liver, and bone marrow function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers access to ulixertinib, an oral drug that targets specific genetic changes (MAPK pathway) in advanced cancers. It is for people who have run out of standard options and may benefit from this targeted treatment.
This early-phase trial tests ulixertinib (a targeted pill) to see how well it works for certain gliomas driven by the MAPK/RAF-MEK-ERK signaling pathway. It also looks at whether the drug can help control tumor growth around the time of treatment planning.
This trial tests whether the drug ulixertinib, combined with cetuximab (and sometimes encorafenib), can help people with advanced or metastatic colorectal cancer who have already tried EGFR or BRAF-targeted therapy. It aims to find new treatment options for these patients.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial tests two drugs, ulixertinib and palbociclib, taken together to see if they can shrink tumors in patients with advanced pancreatic cancer, melanoma, or other solid tumors. It may be an option for people who have already tried standard treatments.
This trial is testing a new targeted pill (luvometinib) alone or with another drug (cytarabine) for people with Langerhans cell histiocytosis that needs whole-body treatment. The goal is to see if the new approach can shrink or control the disease.
Hear when a new Histiocytic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.